BofA analyst Jason Gerberry raised the firm’s price target on Harmony Biosciences (HRMY) to $32 from $31 and keeps an Underperform rating on the shares after the company pre-announced Q4 revenue of $201M, versus consensus of $200M. On 2025 guidance, Harmony expects Wakix sales of $820M-$860M versus consensus at $851M, noted the analyst, who updated the firm’s model to reflect updated results and raised its 2025 revenue forecast to $838M from $820M.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY: